Skip to main content
. 2021 Apr 8;38(6):2936–2952. doi: 10.1007/s12325-021-01707-9

Table 3.

Results of a subgroup analysis of mean SBM by sex, age, race, and SBM at baseline

Mean SBM count (SD), n Lubiprostone sprinkle (n = 234) Lubiprostone capsule (n = 113) Placebo (n = 126)
Baseline Week 1 Baseline Week 1 Baseline Week 1
Sex
 Male 1.3 (0.67), 32 3.1 (2.04), 32 1.3 (0.66), 21 5.2 (3.72), 21 1.3 (0.49), 21 3.1 (1.61), 21
 Female 1.4 (0.70), 202 5.1 (3.79), 202 1.3 (0.74), 92 5.9 (3.81), 92 1.4 (0.73), 105 3.8 (2.25), 105
Age
 < 65 1.4 (0.70), 213 4.8 (3.75), 213 1.4 (0.71), 100 5.7 (3.80), 100 1.4 (0.68), 118 3.7 (2.14), 118
 ≥ 65 1.4 (0.58), 21 4.8 (2.62), 21 1.3 (0.83), 13 6.3 (3.79), 13 1.2 (0.88), 8 3.0 (2.51), 8
Race
 White 1.3 (0.66), 120 4.7 (3.60), 120 1.3 (0.69), 59 4.9 (2.87), 59 1.4 (0.7), 71 3.6 (1.97), 71
 Non-white 1.4 (0.73), 114 4.9 (3.73), 114 1.4 (0.76), 54 6.6 (4.45), 54 1.3 (0.69), 55 3.7 (2.41), 55
SBM at baseline
 < 1.5 0.8 (0.46), 102 4.3 (3.20), 102 0.7 (0.42), 47 5.7 (4.89), 47 0.8 (0.46), 56 3.2 (2.10), 56
 ≥ 1.5 1.8 (0.43), 132 5.2 (3.94), 132 1.8 (0.43), 66 5.7 (2.79), 66 1.9 (0.40), 70 4.1 (2.15), 70

SBM spontaneous bowel movement, SD standard deviation